Document:

CONSULTING AGREEMENT

                                                                   EXHIBIT 10.21

      This CONSULTING AGREEMENT (the "Agreement") is made by and between
Pharm-Olam International Ltd., a Texas limited partnership with an address of
450 North Sam Houston Pkwy., Suite 250, Houston, TX 77060 ("Consultant"), and
Advaxis, Inc., with an address of 212 Carnegie Center, Suite 206, Princeton, New
Jersey 08540 ("Advaxis") and is effective as of January 15, 2005 ("Effective
Date").

                                    RECITALS

A.    Consultant, a contract research organization, possesses special expertise
      and knowledge in the field of pre-clinical, clinical and regulatory
      affairs; and

B.    Advaxis, a biotechnology company commercializing novel vaccines, has need
      for Consultant's pre-clinical consultant services; and

C.    Advaxis and Consultant now desire to enter into this Agreement whereby
      Consultant shall perform consulting services for Advaxis on the terms and
      conditions set forth below.

                                   AGREEMENT

NOW, THEREFORE, Consultant and Advaxis agree as follows:

1.    Description of Services. Subject to the terms and conditions of this
      Agreement, Consultant shall perform management of pre-clinical toxicology
      studies as defined in Attachment 1 and by cost in Attachment 2. Timelines
      for pre-clinical toxicology studies milestone payment schedule are
      outlined in Attachment 3

2.    Term and Renewal. This Agreement shall be effective as of the Effective
      Date and shall remain in effect for a period of Twelve (12) months unless
      terminated pursuant to this Agreement. This Agreement may only be renewed
      for additional periods on terms mutually agreed upon in writing by the
      parties. Neither party shall have any obligation to renew this Agreement.
      However, the expiration of this Agreement shall not effect the obligations
      of Consultant to complete the services agreed upon in this Agreement.

3.    Fees.

      a)    For return of services as outlined in Attachment 1 and 2, Advaxis
            will make milestone payments according to payment chart in
            Attachment 3. The cost for project management, animal studies and
            DNA assays as outlined in Attachment 2 is $272,163, two hundred
            seventy two one hundred sixty three dollars.

      b)    Advaxis shall also reimburse Consultant for all reasonable and
            necessary out-of-scope expenses actually incurred by Consultant in
            rendering services under this Agreement. In case of meetings, such
            expenses will include reasonable and necessary travel, lodging and
            meals. Consultant shall provide Advaxis with a written expense
            report, complete with receipts or other reasonable documentation,
            for all such expenses requested for reimbursement. Any expense item
            greater than $200 shall require Advaxis' prior written or email
            approval.

<PAGE>

4.    Invoices. Milestone payments due hereunder shall be payable upon Advaxis's
      receipt ("Due Date") of a written invoice or an expense report and
      accompanying supporting documentation therefore. Any amounts which remain
      unpaid for thirty (30) days or more after the Due Date shall bear interest
      at the rate equal to 8%. Interest shall be computed on the basis of 12
      months of 30 days each per year, as the case may be, subject to the
      provisions hereof limiting interest to the maximum rate of interest
      allowed by applicable law.

5.    Confidentiality; Proprietary Information; Intellectual Property.

      a)    Any and all information which Advaxis or its affiliates may disclose
            to Consultant under this Agreement will be considered confidential.

      b)    Consultant further agrees that all discussions and negotiations with
            respect to this Agreement are confidential.

      c)    Consultant understands that Advaxis possesses and will continue to
            possess information that has been created, discovered or developed,
            or has otherwise become known to Advaxis or its affiliates and/or in
            which property rights have been assigned or otherwise conveyed to
            Advaxis or its affiliates, which information has commercial value in
            the business in which Advaxis is engaged. All such information,
            including the information described in Sections 5 (a) and (b) above,
            and including any other information developed by or on behalf of
            Consultant pursuant to this Agreement, is hereinafter referred to as
            "Proprietary Information." By way of illustration, but not
            limitation, Proprietary Information includes trade secrets,
            processes, formulae, data and know-how, improvements, inventions,
            techniques, marketing plans, strategies, forecasts and customer and
            contact lists. Accordingly, Consultant further agrees as follows:

                  i)    All Proprietary Information shall be the sole property
                        of Advaxis or its affiliates and their assigns, as the
                        case may be, and such parties shall be the sole owners
                        of all patents and other rights in connection therewith.
                        At all times during this Agreement and at all times
                        after expiration or termination of this Agreement,
                        Consultant will keep in confidence and trust all
                        Proprietary Information, and will not use or disclose
                        any Proprietary Information without the prior written
                        consent of Advaxis, except as may be necessary in the
                        ordinary course of performing the duties of Consultant
                        hereunder. No announcement, oral presentation or
                        publication of any kind relating to any Proprietary
                        Information shall be made by Consultant without the
                        prior written consent of Advaxis; and
<PAGE>

                  ii)   All documents, data, records, apparatus, equipment and
                        other physical property, whether or not pertaining to
                        Proprietary Information, furnished to Consultant by or
                        on behalf of Advaxis or developed by or on behalf of
                        Consultant pursuant to this Agreement, shall be and
                        remain the sole property of Advaxis and/or its
                        affiliates and shall be returned promptly as and when
                        requested by Advaxis. Should Advaxis not so request,
                        Consultant agrees to return and deliver all such
                        property upon expiration or termination of this
                        Agreement for any reason and Consultant shall not retain
                        or reproduce any such property upon expiration or
                        termination.

                  iii)  Consultant shall promptly disclose to Advaxis or its
                        designee all intellectual property (including, but not
                        limited to any inventions, improvements, formulae,
                        processes, techniques, know-how, data, patents or
                        applications for patents, trade secrets, trademarks,
                        copyrights and confidential information as described in
                        this Section 5), made or conceived or reduced to
                        practice or learned by Consultant (collectively,
                        "Intellectual Property") which (A) result from the tasks
                        assigned to Consultant hereunder; (B) are funded by or
                        on behalf of Advaxis or its affiliates; or (C) result
                        from the use or property or premises owned, leased or
                        contracted for by or on behalf of Advaxis or its
                        affiliates.

                  iv)   Consultant agrees to and does hereby sell, assign,
                        transfer and set over to Advaxis, its affiliates,
                        successors or assigns, as the case may be, all right,
                        title and interest in and to all Intellectual Property
                        developed or conceived individually or in conjunction
                        with others in performance of this Agreement, to be held
                        and enjoyed by Advaxis, its affiliates, successor or
                        assigns, as the case may be, to the full extent of the
                        term for which any Letters Patent may be granted and as
                        fully as the Intellectual Property would have been held
                        by Consultant had this Agreement, sale or assignment not
                        be made.

                  v)    Consultant shall execute and deliver any and all
                        instruments and documents and perform any and all acts,
                        necessary to obtain, maintain or enforce patents,
                        trademarks, trade secrets and copyrights for such
                        Intellectual Property, and shall make, execute and
                        deliver any and all instruments and documents and
                        perform any and all acts necessary to obtain, maintain
                        or enforce patents, trademarks, trade secrets and
                        copyrights for such Intellectual Property as Advaxis may
                        designate in any and all countries. All costs and
                        expenses of application and prosecution of such patents,
                        trademarks, trade secrets and copyrights shall be paid
                        by Advaxis.

                  vi)   Any copyrightable material prepared by Consultant as a
                        result of Consultant's activities with Advaxis, in
                        performance of this Agreement, are prepared as works for
                        hire for the benefit of Advaxis. Consultant hereby
                        assigns to Advaxis any copyright to which Consultant is
                        entitled for any copyrightable material prepared in the
                        course of the performance of this Agreement for Advaxis.
                        Advaxis shall have the right to reproduce, modify and
                        use such material and all results generated as the
                        result of services rendered under this Agreement for any
                        propose related to its lawful business.

<PAGE>

                  vii)  Upon the written request of Advaxis, Consultant shall
                        make any assignment provided for in this Section 5
                        directly to, or for the benefit of, an Advaxis affiliate
                        or Advaxis's designee, including Consultant's
                        performance of any related obligations hereunder.

6.    Remedies. (a) Consultant acknowledges that Advaxis will have no adequate
      remedy at law if Consultant breaches the terms of Section 5 hereof.
      Accordingly, in such event, Advaxis shall have the right, in addition to
      any other rights it may have at law or equity, to obtain in any tribunal
      of competent jurisdiction injunctive relief to restrain any breach or
      threatened breach. (b) If, due to reasons within Consultant's reasonable
      control, Consultant's products or services fail to meet standards
      generally accepted in the applicable industry, or if Consultant fails to
      provide agreed-upon products or services in a timely manner Advaxis shall
      have the right, in addition to any other remedy it may have at law or
      equity, to: (i) terminate this Agreement immediately upon written notice
      to Consultant; (ii) require that defective products or services be
      replaced or remedied, as the case may be, without charge to Advaxis; and
      (iii) correct, or have corrected by a third party, the defective product
      or service and withhold from amounts owing to Consultant hereunder all
      amounts incurred by Advaxis in taking such corrective measures.

7.    Termination. This Agreement may be terminated (a) by Advaxis with or
      without cause upon thirty (30) day's prior written notice to Consultant,
      or (b) by Consultant in the event of a material breach by Advaxis,
      provided that Consultant provides Advaxis with written notice of such
      breach and Advaxis fails reasonably to cure such breach within thirty (30)
      days of receipt of such notice.

      In the event this Agreement is terminated pursuant to this Section prior
      to completion of the work to be performed, Consultant shall cease work
      upon Advaxis's request, and shall be entitled to receive its fee for work
      actually and reasonably performed through the effective date of
      termination. In addition, Consultant shall promptly return to Advaxis all
      written materials and biological material provided to Consultant by
      Advaxis or its partners or affiliates.

      The provisions of Sections 5-6 and 9-14, inclusive, shall survive
      expiration or termination of this Agreement.

8.    Independent Contractor. Consultant shall be an independent contractor and
      shall have no authority to enter into contracts on behalf of Advaxis, bind
      Advaxis to any third parties or act as an agent on behalf of Advaxis in
      any way. Consultant shall account for and report the payment of all
      applicable federal and state income taxes, social security taxes, and all
      other taxes due on payments received by Consultant hereunder. Consultant
      hereby acknowledges than Advaxis will report as compensation all payments
      to Consultant hereunder.

<PAGE>

9.    Consultant's Representation and Warranties. Consultant hereby represents
      and warrants to Advaxis that (a) Consultant has the authority to enter
      into and perform this Agreement and (b) performance of Consultant's
      services as contemplated by this Agreement will not result in the breach
      or violation of any contract, arrangement or understanding (including
      without limitation any intellectual property rights or any agreement of
      confidentiality or non-disclosure, whether written or oral) which
      Consultant may have with any third party (including with limitation
      current and former employers of Consultant and any other companies or
      persons for which Consultant has performed or is performing consulting
      services).

10.   Compliance Standards. During the term of this Agreement and any renewal
      term, Consultant shall comply with all applicable laws, rules and
      regulations in the conduct of the services being performed.

11.   Severability. If any provision of this Agreement is declared void or
      unenforceable, such provision shall be deemed modified to the extent
      necessary to allow enforcement, and all other portions of this Agreement
      shall remain in full force and effect.

12.   Entire Agreement, Amendments. This Agreement contains the entire and
      complete agreement between the parties with respect to the subject matter
      hereof, and supersedes all prior oral and/or written agreements with
      respect to the subject matter hereof, other than any currently effective
      confidentiality agreement. Any changes to this Agreement must be in
      writing and signed by both parties. The Parties acknowledge that the
      confidentiality agreement previously executed beween the parties remain in
      full force and effect.

13.   Successors. This Agreement shall be binding upon and inure to the benefit
      of the successors, assigns and legal representatives of the parties.

14.   Governing Law. This Agreement shall be governed by and construed in
      accordance with the laws of the State of New Jersey without regard to its
      conflicts of laws provisions, and the parties agree to personal
      jurisdiction and venue in the state and federal courts of New Jersey, in
      any suit or proceeding arising out of the subject matter of this
      Agreement.

DATED as of the Effective Date written above, and executed by:

ADVAXIS, INC.:

By:  /s/ J. Todd Derbin
     -------------------------
     Name: J. Todd Derbin
     Title: CEO

<PAGE>

PHARM-OLAM INTERNATIONAL LTD.:

By:___________________________
     Name:
     Title:

                                  ATTACHMENT 1

             FOUR WEEK TOXICOLOGY STUDY OF LM-LLO-E7 VECTOR IN MICE

PURPOSE: To examine the toxicity of Advaxis' Lm-LLO-E7 Vector following four
weekly i.v. or s.c. doses to female Balb/C mice.

SCOPE: 10 mice/group
       70 FEMALE MICE TOTAL

REGULATORY STATUS: GLP

TEST ARTICLE: Lm-LLO-E7

CONTROL ARTICLES: Control Buffer

ROUTES OF ADMINISTRATION:  i.v./s.c.

OVERALL DESIGN:
Wild-Type female Balb/C mice will be administered a single intravenous or
subcutaneous injection of Lm-LLO-E7 Vector or control saline once weekly for
four weeks on Study Days 1, 8, 15 and 22 as described in the table below.

<TABLE>
<CAPTION>
===========================================================================================================
                          FOUR WEEK TOXICOLOGY STUDY OF LM-LLO-E7 IN FEMALE MICE
-----------------------------------------------------------------------------------------------------------
   Group           Treatment              Dose Level          Route        Dosing Days         Females
============ ======================= ====================== ========== ==================== ===============
<S>                <C>                       <C>              <C>          <C>                   <C>
     1               Saline                    0              i.v.         1,8,15, 22             10
------------ ----------------------- ---------------------- ---------- -------------------- ---------------
     2             Lm-LLO-E7                  Low             i.v.         1,8,15, 22             10
------------ ----------------------- ---------------------- ---------- -------------------- ---------------
     3             Lm-LLO-E7                  Mid             i.v.         1,8,15, 22             10
------------ ----------------------- ---------------------- ---------- -------------------- ---------------
     4             Lm-LLO-E7                 High             i.v.         1,8,15, 22             10
============ ======================= ====================== ========== ==================== ===============
     5             Lm-LLO-E7                  Low             s.c.         1,8,15, 22             10
------------ ----------------------- ---------------------- ---------- -------------------- ---------------
     6             Lm-LLO-E7                  Mid             s.c.         1,8,15, 22             10
------------ ----------------------- ---------------------- ---------- -------------------- ---------------
     7             Lm-LLO-E7                 High             s.c.         1,8,15, 22             10
============ ======================= ====================== ========== ==================== ===============
</TABLE>

<PAGE>

IN-LIFE PROCEDURES:

o     CLINICAL OBSERVATIONS: Twice Daily cageside observation for signs of
      mortality, moribundity and/or toxicity.

o     PHYSICAL EXAMS, BODY WEIGHTS AND FOOD CONSUMPTION: At randomization, prior
      to treatment on SD1 and weekly thereafter.

TERMINAL PROCEDURES:

Twenty-four hours following the final dose:

o     Blood samples are obtained from all surviving mice for clinical pathology
      and hematological analysis. (5 animals for hematology, 5 for clinical
      chemistry per group)

o     Body weights

o     Necropsy:

Full gross necropsy on all main study mice, and will include examination of
external surface of body, all orifices, and cranial, thoracic and abdominal
cavities and their contents. The following tissues will be obtained at necropsy
and preserved in neutral buffered formalin:

<TABLE>
<CAPTION>
---------------------- -------------- ----------- ---------------- --------------- -------------- ---------- ---------------
<S>                    <C>            <C>         <C>              <C>             <C>            <C>        <C>
Adrenals               Aorta          Bone        Brain            Cecum           Colon          Cervix     Duodenum
---------------------- -------------- ----------- ---------------- --------------- -------------- ---------- ---------------
epididymides           Esophagus      Eyes        Femur            Gallbladder     Heart          Ileum      Jejunum
---------------------- -------------- ----------- ---------------- --------------- -------------- ---------- ---------------
Kidneys                Liver          Lungs       Lymph nodes      Salivary gl     Mammary Gl     Optic      Ovaries
                                                                                                  nerves
---------------------- -------------- ----------- ---------------- --------------- -------------- ---------- ---------------
Pancreas               Pituitary      Gross       Sciatic Nerve    Skin            Spinal cord    Spleen     Stomach
                                      Lesions

---------------------- -------------- ----------- ---------------- --------------- -------------- ---------- ---------------
Administration Site    Thymus         Thyroid     Parathyroid      Trachea         Skeletal       Vagina     Uterus
                                                                                   Muscle
---------------------- -------------- ----------- ---------------- --------------- -------------- ---------- ---------------
</TABLE>

All Tissues from control and high dose treated animals will be embedded in
paraffin, stained with hematoxylin and eosin, and examined microscopically by a
board certified veterinary pathologist. Tissues from the mid and low dose group
will be retained and evaluated only if findings were noted in corresponding
tissues from high dose treated animals.

TEST ARTICLE DOSAGE VERIFICATION:

      INFORMATION TO BE SUPPLIED BY THE SPONSOR. (REQUIRED FOR GLP STUDY)

<PAGE>

              ACUTE DOSE TOXICITY STUDY OF LM-LLO-E7 IN BALB/C MICE

PURPOSE:

o     To determine the Maximum Tolerated Dose (MTD) of Lm-LLO-E7 Vector via both
      s.c. and i.v. routes to female Balb/C

o     To compare the tolerability of Balb/C mice to Lm-LLO-E7 relative to WT
      Listeria

RATIONALE:

o     24 Female mice for Dose Range phase.

o     Only females will be used since the indication for Lm-LLO-E7 is Cervical
      Cancer

o     No difference is anticipated between sexes

o     Balb/c mice will be used since they are more sensitive to Listeria than
      C57BL/6 Mice.

o     LD50 for Lm-LLO-E7 in Balb/c mice is reported to be ~108 pfu via ip route.

o     Sensitivity to i.v. route of administration should be greater.

o     Dose levels will be adjusted based on results of initial determinations
      from groups 3 and 6 below.

STUDY DESCRIPTION:

Test Article:  Lm-LLO-E7 Listeria Monocytogenes Bacterial Vector
Control Article:  WT Listeria Monocytogenes Vector

ROUTE OF ADMINISTRATION:  Intravenous or subcutaneous (as indicated)

A.    DOSE RANGE FINDING TOXICITY PHASE:

<TABLE>
<CAPTION>
==========================================================================================================
               ACUTE DOSE RANGE FINDING TOXICITY STUDY OF LM-LLO-E7 VECTOR IN BALB/C MICE
------------ ---------------------------- ------------------------ -------------- ------------------------
   GROUP              TREATMENT                 DOSE LEVEL               ROUTE       NUMBER OF FEMALES
                                                   (PFU)
------------ ---------------------------- ------------------------ -------------- ------------------------
<S>                  <C>                           <C>                 <C>                   <C>
     1               WT Listeria                    MTD                i.v.                  3
------------ ---------------------------- ------------------------ -------------- ------------------------
     2               WT Listeria                    MTD                s.c.                  3
============ ============================ ======================== ============== ========================
     3                Lm-LLO-E7                     106                i.v.                  3
------------ ---------------------------- ------------------------ -------------- ------------------------
     4                Lm-LLO-E7                    107*                i.v.                  3
------------ ---------------------------- ------------------------ -------------- ------------------------
     5                Lm-LLO-E7                    108*                i.v.                  3
------------ ---------------------------- ------------------------ -------------- ------------------------
     6                Lm-LLO-E7                     106                s.c.                  3
------------ ---------------------------- ------------------------ -------------- ------------------------
     7                Lm-LLO-E7                    107*                s.c.                  3
------------ ---------------------------- ------------------------ -------------- ------------------------
     8                Lm-LLO-E7                    108*                s.c.                  3
============ ============================ ======================== ============== ========================
*Based on results of dosing groups 3 and 6 mice.
</TABLE>

o     Groups 1-2 female Balb/c mice will receive a single i.v. or s.c. dose of
      WT Listeria on study Day 1 and will be monitored for signs of toxicity.
      This dose will be based on published data on the known toxicity of WT
      listeria.

o     Mice in groups 3-5 will be dosed i.v. with increasing doses of LmLLO-E7
      starting at 106 pfu. If this dose is well tolerated, a higher dose will be
      administered until a MTD is established.
<PAGE>

o     Mice in groups of 6-8 will be dosed s.c. with increasing doses of LmLLO-E7
      starting at 106 pfu. If this dose is well tolerated, a higher dose will be
      administered until a MTD is established.

B. MAIN PHASE ACUTE TOXICITY STUDY

Groups of 5 female mice will be dosed once on Study Day 1 as described in the
table below. Mice will be administered a single i.v. or s.c. injection of the
Lm-LLO-E7 Vector or WT Listeria (Groups 1-2) on Study Day 1.

Mice will be observed for clinical signs and changes in body weight and food
consumption during the next 14 days. Surviving mice will be sacrificed on Study
day 15, and gross necropsies will be performed.

<TABLE>
<CAPTION>
==========================================================================================================
                 ACUTE DOSE IV AND SC TOXICITY STUDY OF LM-LLO-E7 VECTOR IN BALB/C MICE
----------------------------------------------------------------------------------------------------------
   GROUP              TREATMENT                 DOSE LEVEL               ROUTE       NUMBER OF FEMALES
                                                   (PFU)
------------ ---------------------------- ------------------------ -------------- ------------------------
<S>                  <C>                      <C>                      <C>                  <C>
     1               WT Listeria              MTD (sub LD50)           i.v.                  5
------------ ---------------------------- ------------------------ -------------- ------------------------
     2               WT Listeria              MTD (sub LD50)           s.c.                  5
============ ============================ ======================== ============== ========================
     3                Lm-LLO-E7                     106                i.v.                  5
------------ ---------------------------- ------------------------ -------------- ------------------------
     4                Lm-LLO-E7                    107*                i.v.                  5
------------ ---------------------------- ------------------------ -------------- ------------------------
     5                Lm-LLO-E7                    108*                i.v.                  5
============ ============================ ======================== ============== ========================
     6                Lm-LLO-E7                     106                s.c.                  5
------------ ---------------------------- ------------------------ -------------- ------------------------
     7                Lm-LLO-E7                    107*                s.c.                  5
------------ ---------------------------- ------------------------ -------------- ------------------------
     8                Lm-LLO-E7                    108*                s.c.                  5
============ ============================ ======================== ============== ========================
</TABLE>

o     Mice will be dosed once as described in the table above either i.v. or
      s.c., and will be monitored for clinical signs of toxicity.

o     Other assessments will include weekly body weights and food consumption.

o     Surviving mice will be weighed and sacrificed on SD 15. Gross necropsies
      only. Only gross lesions to be retained.

<PAGE>

             PILOT BIODISTRIBUTION STUDY OF LM-LLO-E7 IN FEMALE MICE

PURPOSE: The purpose of this pilot study is to determine the biodistribution of
Lm-LLO-E7 vector following a single i.v. administration to female Balb/c mice,
and to optimize conditions for PCR detection of Lm-LL0-E7 following i.v.
administration in mice.

<TABLE>
<CAPTION>
=============================================================================================================
                          PILOT BIODISTRIBUTION OF LM-LLO-E7 VECTOR IN FEMALE MICE
-------------------------------------------------------------------------------------------------------------
   GROUP          TREATMENT         DOSE LEVEL          ROUTE OF           FEMALES     SCHEDULED SACRIFICES
                                                     ADMINISTRATION                      (3 PER TIMEPOINT)
============ ===================== ============== ===================== ============== ======================
<S>           <C>                   <C>               <C>                    <C>           <C>
     1          Buffer Control           0            Intravenous             4                 SD2
------------ --------------------- -------------- --------------------- -------------- ----------------------
     2         Lm-LLO-E7 Vector     108 CFU or        Intravenous            12            SD 2, 10, 30
                                        MTD
============ ===================== ============== ===================== ============== ======================
</TABLE>

CLINICAL OBSERVATIONS: Twice daily cageside observation for signs of mortality,
moribundity and/or toxicity

PHYSICAL EXAMS: At randomization, prior to treatment on SD1 and weekly
thereafter.

BODY WEIGHTS: At randomization, prior to treatment on SD1 and weekly thereafter.

TERMINAL PROCEDURES: On study day 2, three mice from groups 1 and 2 will be
weighed, bled, and sacrificed by CO2 asphyxiation. Blood samples and tissue
samples will be obtained and will be analyzed for presence of exogenous Test
article DNA using PCR with primers specific for the vector and/or targeted gene.
On study days 10 and 30 respectively, three mice per day from group 2 will be
weighed, bled and sacrificed and blood and tissue samples obtained and analyzed
for exogenous Test article DNA.

o     Gross necropsies will be performed only to obtain Tissues for PCR
      analysis.

o     A portion of the following tissues will be collected using clean sterile
      instruments (clean sterile set for each individual animal) and placed in
      vials and frozen at -80(Degree)C:

         Injection Site             Spleen                    Small Intestine
         Ovaries                    Lymph node (1)            Lung
         Heart                      Brain                     Bone Marrow
         Kidney                     Liver                     Blood

PCR ANALYSIS: PCR analysis will be performed on the tissues using primers
specific for genetic sequences of the Listeria monocytogenes vector.

TEST ARTICLE DOSAGE VERIFICATION: Information to be supplied by the sponsor.

<PAGE>

                   BIODISTRIBUTION OF LM-LLO-E7 VECTOR IN MICE

PURPOSE: To examine the biodistribution of Lm-LLO-E7 Vector following a single
intravenous or s.c. injection to female Balb/C mice.

SCOPE: 96 Female Mice

REGULATORY STATUS: GLP

TEST ARTICLE: Lm-LLO-E7

CONTROL ARTICLES: Control Buffer

ROUTES OF ADMINISTRATION: Intravenous and Subcutaneous

PURPOSE: To compare overall biodistribution following either i.v. or s.c.
administration of Lm-LLO-E7.

OVERALL DESIGN: Wild-Type female Balb/c mice will be administered a single
intravenous or s.c. injection of Lm-LLO-E7 Vector or control saline on Study Day
1 (SD 1) as described in the table below. Six mice per timepoint will be dosed,
but only five per timepoint will be sacrificed for PCR analysis.

<TABLE>
<CAPTION>
=============================================================================================================
                        BIODISTRIBUTION OF LM-LLO-E7 LISTERIA VECTOR IN FEMALE MICE
-------------------------------------------------------------------------------------------------------------
   Group         Treatment          Dose Level           Route           Dose Volume          Females
                                                                           (mL/kg)
============ =================== ================= =================== ================ =====================
<S>               <C>                 <C>                 <C>               <C>                 <C>
     1             Saline               0                 i.v.               10                  24
------------ ------------------- ----------------- ------------------- ---------------- ---------------------
     2           Lm-LLO-E7             Low                i.v.               10                  24
                   Vector
------------ ------------------- ----------------- ------------------- ---------------- ---------------------
     3           Lm-LLO-E7             High               i.v.               10                  24
                   Vector
------------ ------------------- ----------------- ------------------- ---------------- ---------------------
     4           Lm-LLO-E7             High               S.C.               10                  24
                   Vector
============ =================== ================= =================== ================ =====================
</TABLE>

CLINICAL OBSERVATIONS: Twice Daily cageside observation for signs of mortality,
moribundity and/or toxicity

PHYSICAL EXAMS: At randomization, prior to treatment on SD1 and weekly
thereafter.

BODY WEIGHTS: At randomization, prior to treatment on SD1 and weekly thereafter.

TERMINAL PROCEDURES: On study days 2, 10 and 30 and 90, five mice per group will
be weighed, bled, and sacrificed by CO2 asphyxiation.

<PAGE>

Blood samples will be analyzed for presence of exogenous Test article DNA using
PCR with primers specific for the vector and target gene.

Gross necropsies will be performed only to obtain Tissues for PCR analysis.

A portion of the following tissues will be collected using clean sterile
instruments (clean sterile set for each individual animal) and placed in small
microcentrifuge vials and frozen at -80(Degree)C:

         Injection Site             Spleen                    Blood
         Ovaries                    Mesentary lymph node      Lung
         Heart                      Brain                     Bone Marrow
         Kidney                     Liver                     Small Intestine

PCR ANALYSIS: Quantitative PCR will be performed on DNA extracted from above
tissue samples and the presence of the vector sequence will be assessed.

TEST ARTICLE DOSAGE VERIFICATION: INFORMATION TO BE SUPPLIED BY THE SPONSOR.
(REQUIRED FOR GLP STUDY)

<PAGE>

                                  ATTACHMENT 2

                    PRE-CLINICAL TOXICOLOGY STUDIES LM-LLO-E7
<TABLE>
<CAPTION>

---------------------------------------------------------------------------------------- --------------------
                                         TASK                                                   COST
---------------------------------------------------------------------------------------- --------------------
<S>                                                                                          <C>
Acute Dose Toxicity and Main Phase
Includes dose range finding to find MTD (24 mice) and main phase acute toxicity (40
mice), assessments of weekly body weights and food consumption, and gross pathology
with necropsy at 15 days, final clinical and GLP reports.                                      $10,632
---------------------------------------------------------------------------------------- --------------------
                                  FOUR WEEK TOXICITY STUDY
Includes four weekly vaccinations given to 70 mice, sacrifice at 28 days, chemistry
and hematology labs. on 50% of mice, gross pathology, final clinical and GLP reports.          $31,500

Histology and pathology of 40 tissues per mouse in control and high dose groups (30
mice) by certified veterinary pathologist with histo-pathology report ($25.00 per              $30,000
tissue)
---------------------------------------------------------------------------------------- --------------------
                                PILOT BIODISTRIBUTION STUDY
Includes 16 mice dosed with 12 serial sacrificed out to 30 days, blood and 11 tissues
per mouse collected for PCR analysis of vector and targeted gene, clinical and GLP             $13,000
reports.
---------------------------------------------------------------------------------------- --------------------
                                   BIODISTRIBUTION STUDY
Includes 96 mice dosed with 80 serial sacrificed out to 90 days, daily clinical
observations, weekly physical exams and body weights, blood and 11 tissues taken
for $31,700 PCR analysis of vector and targeted gene, clinical and GLP reports.
---------------------------------------------------------------------------------------- --------------------
                                        PCR ANALYSIS
Lark will analyze 11 tissues and one blood from 3 groups of mice (12, 60 and 20)
using a targeted assay. Lark will also perform spiking experiments on all
samples and extraction efficiency tests. The reactions will be thermal cycled,
recorded and analyzed using the ABI PRISM 7700 Sequence Detection System. All
work will be $135,831 conducted under Good Laboratory Practices.
---------------------------------------------------------------------------------------- --------------------
                                     PROJECT MANAGEMENT
Pharm-Olam will management all the studies to assure conducted to Good Laboratory
Practices and compliant with the protocol, monitor studies at critical points, weekly
sponsor updates, oversee development of all protocols and clinical reports and                 $19,500
maintain study timelines.  (130 hours @ $150/hr)
---------------------------------------------------------------------------------------- --------------------
                                                                           TOTAL              $272,163

---------------------------------------------------------------------------------------- --------------------
If the histo-pathology is needed for the medium and low dose (40 mice) in the 4
week study, the cost will be another $40,000.
</TABLE>

<PAGE>

                                  ATTACHMENT 3

     TIMELINES FOR PRE-CLINICAL TOXICOLOGY STUDIES

     February 1 - initiate acute dose toxicity study

     March 1 - initiate main phase acute dose toxicity study

     March 1 - initiate pilot bio-distribution study

     April 1 - initiate 4 week multi-dose study

     May 1 - initiate 90 day bio-distribution study

     September 1- Final reports completed for all studies

     MILESTONE PAYMENT CHART

--------------------------------------------------------------------------------
Milestones                                              Percent        Cost
--------------------------------------------------------------------------------
Signing of agreement                                      10%        $27,216.30
--------------------------------------------------------------------------------
Initiation of pilot acute toxicity                        10%        $27,216.30
--------------------------------------------------------------------------------
Initiation of pilot-distribution & 4 main phase studies   20%        $54,432.60
--------------------------------------------------------------------------------
Initiation of 4 week multi-dose study                     20%        $54,432.60
--------------------------------------------------------------------------------
Initiation of 90 day bio-distribution study               20%        $54,432.60
--------------------------------------------------------------------------------
Final  reports completed for all studies                  20%        $54,432.60
--------------------------------------------------------------------------------
Total                                                                  $272,163
--------------------------------------------------------------------------------Exhibit 4.5

 

 

UNIT
PURCHASE OPTION

 

FOR THE
PURCHASE OF

 

700,000
UNITS

 

OF

 

FORTRESS
AMERICA ACQUISITION CORPORATION

TABLE OF CONTENTS

Page

 

	
      1.
	
      PURCHASE
      OPTION.
	
      1

 

	
      2.
	
      EXERCISE.
	
      1

 

	 	
      2.1
	
      Exercise
      Form
	
      1

 

	 	
      2.2
	
      Legend
	
      2

 

	 	
      2.3
	
      Cashless
      Exercise.
	
      2

 

	 	
      2.3.1
	
      Determination
      of Amount
	
      2

 

	 	
      2.3.2
	
      Mechanics of
      Cashless Exercise
	
      2

 

	
      3.
	
      TRANSFER.
	
      3

 

	 	
      3.1
	
      General
      Restrictions
	
      3

 

	 	
      3.2
	
      Restrictions
      Imposed by the Act
	
      3

 

	
      4.
	
      NEW
      PURCHASE OPTIONS TO BE ISSUED.
	
      3

 

	 	
      4.1
	
      Partial
      Exercise or Transfer
	
      3

 

	 	
      4.2
	
      Lost
      Certificate
	
      3

 

	
      5.
	
      REGISTRATION
      RIGHTS.
	
      3

 

	 	
      5.1
	
      Demand
      Registration.
	
      3

 

	 	
      5.1.1
	
      Grant
      of Right
	
      3

 

	 	
      5.1.2
	
      Terms
	
      4

 

	 	
      5.2
	
      “Piggy-Back”
      Registration.
	
      4

 

	 	
      5.2.1
	
      Grant
      of Right
	
      4

 

	 	
      5.2.2
	
      Terms
	
      4

 

	 	
      5.3
	
      Damages
	
      5

 

	 	
      5.4
	
      General
      Terms.
	
      5

 

	 	
      5.4.1
	
      Indemnification
	
      5

 

	 	
      5.4.2
	
      Exercise of
      Purchase Options
	
      5

 

	 	
      5.4.3
	
      Documents
      Delivered to Holders
	
      5

 

	 	
      5.4.4
	
      Underwriting
      Agreement
	
      6

 

	 	
      5.4.5
	
      Rule
      144 Sale
	
      6

 

	 	
      5.4.6
	
      Supplemental
      Prospectus
	
      6

 

	
      6.
	
      ADJUSTMENTS.
	
      6

 

	 	
      6.1
	
      Adjustments
      to Exercise Price and Number of Securities
	
      6

 

	 	
      6.1.1
	
      Stock
      Dividends - Split-Ups
	
      6

 

	 	
      6.1.2
	
      Aggregation
      of Shares
	
      7

 

	 	
      6.1.3
	
      Replacement
      of Securities upon Reorganization, etc
	
      7

 

	 	
      6.1.4
	
      Changes
      in Form of Purchase Option
	
      7

 

ii

	 	
      6.2
	
      [Intentionally
      Omitted].
	
      7

 

	 	
      6.3
	
      Substitute
      Purchase Option
	
      7

 

	 	
      6.4
	
      Elimination
      of Fractional Interests
	
      7

 

	
      7.
	
      RESERVATION
      AND LISTING
	
      8

 

	
      8.
	
      CERTAIN
      NOTICE REQUIREMENTS.
	
      8

 

	 	
      8.1
	
      Holder’s
      Right to Receive Notice
	
      8

 

	 	
      8.2
	
      Events
      Requiring Notice
	
      8

 

	 	
      8.3
	
      Notice
      of Change in Exercise Price
	
      8

 

	 	
      8.4
	
      Transmittal
      of Notices
	
      8

 

	
      9.
	
      MISCELLANEOUS.
	
      9

 

	 	
      9.1
	
      Amendments
	
      9

 

	 	
      9.2
	
      Headings
	
      9

 

	
      10.
	
      ENTIRE
      AGREEMENT
	
      9

 

	 	
      10.1
	
      Binding
      Effect
	
      9

 

	 	
      10.2
	
      Governing
      Law; Submission to Jurisdiction
	
      9

 

	 	
      10.3
	
      Waiver,
      Etc
	
      9

 

	 	
      10.4
	
      Execution in
      Counterparts
	
      9

 

	 	
      10.5
	
      Exchange
      Agreement
	
      10

 

	 	
      10.6
	
      Underlying
      Warrants
	
      10

 

 

iii

THE
REGISTERED HOLDER OF THIS PURCHASE OPTION BY ITS ACCEPTANCE HEREOF, AGREES THAT
IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE OPTION EXCEPT AS HEREIN
PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE OPTION AGREES THAT IT WILL
NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE OPTION FOR A
PERIOD OF ONE YEAR FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE OTHER
THAN (I) SUNRISE SECURITIES CORP. (“SUNRISE”) OR AN UNDERWRITER OR A SELECTED
DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER
OF SUNRISE OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS
PURCHASE OPTION IS NOT EXERCISABLE PRIOR TO THE LATER OF (I) ______________,
2006 AND (II) THE CONSUMMATION BY FORTRESS AMERICA ACQUISITION CORPORATION
(“COMPANY”) OF A MERGER, CAPITAL STOCK EXCHANGE, ASSET ACQUISITION OR OTHER
SIMILAR BUSINESS COMBINATION (“BUSINESS COMBINATION”) (AS DESCRIBED MORE FULLY
IN THE COMPANY’S REGISTRATION STATEMENT (DEFINED HEREIN)). VOID AFTER 5:00 P.M
EASTERN TIME, _____________, 2010.

 

UNIT
PURCHASE OPTION

 

FOR THE
PURCHASE OF

 

700,000
UNITS

 

OF

 

FORTRESS
AMERICA ACQUISITION CORPORATION

 

1.  Purchase
Option.

 

 

THIS
CERTIFIES THAT, in consideration of $_____ duly paid by or on behalf of
____________________ (“Holder”), as registered owner of this Purchase Option, to
Fortress America Acquisition Corporation (“Company”), Holder is entitled, at any
time or from time to time upon the later of (i) ___________, 2006 and (ii) the
consummation of a Business Combination (“Commencement Date”), and at or before
5:00 p.m., Eastern Time, _____________, 2010 (“Expiration Date”), but not
thereafter, to subscribe for, purchase and receive, in whole or in part, up to
Seven Hundred Thousand (700,000) units (“Units”) of the Company, each Unit
consisting of one share of common stock of the Company, par value $.0001 per
share (“Common Stock”), and two warrants (“Warrant(s)”) expiring four years from
the effective date (“Effective Date”) of the registration statement
(“Registration Statement”) pursuant to which Units are offered for sale to the
public (“Offering”). Each Warrant is the same as the warrants included in the
Units being registered for sale to the public by way of the Registration
Statement (“Public Warrants”) except that the Warrants have an exercise price of
$6.25 per share. If the Expiration Date is a day on which banking institutions
are authorized by law to close, then this Purchase Option may be exercised on
the next succeeding day which is not such a day in accordance with the terms
herein. During the period ending on the Expiration Date, the Company agrees not
to take any action that would terminate the Purchase Option. This Purchase
Option is initially exercisable at $7.50 per Unit so purchased; provided,
however, that upon the occurrence of any of the events specified in Section 6
hereof, the rights granted by this Purchase Option, including the exercise price
per Unit and the number of Units (and shares of Common Stock and Warrants) to be
received upon such exercise, shall be adjusted as therein specified. The term
“Exercise Price” shall mean the initial exercise price or the adjusted exercise
price, depending on the context.

 

 

2.  Exercise.

 

2.1  Exercise
Form. In
order to exercise this Purchase Option, the exercise form attached hereto must
be duly executed and completed and delivered to the Company, together with this
Purchase Option and payment of the Exercise Price for the Units being purchased
payable in cash or by certified check or official bank check. If the
subscription rights represented hereby shall not be exercised at or before 5:00
p.m., Eastern time, on the Expiration Date, this Purchase Option shall become
and be void without further force or effect, and all rights represented hereby
shall cease and expire.

 

2.2  Legend. Each
certificate for the securities purchased under this Purchase Option shall bear a
legend as follows unless such securities have been registered under the
Securities Act of 1933, as amended (“Act”):

 

“The
securities represented by this certificate have not been registered under the
Securities Act of 1933, as amended (“Act”) or applicable state law. The
securities may not be offered for sale, sold or otherwise transferred except
pursuant to an effective registration statement under the Act, or pursuant to an
exemption from registration under the Act and applicable state
law.”

 

2.3  Cashless
Exercise.

 

2.3.1  Determination
of Amount. In lieu
of the payment of the Exercise Price multiplied by the number of Units for which
this Purchase Option is exercisable (and in lieu of being entitled to receive
Common Stock and Warrants) in the manner required by Section 2.1, the Holder
shall have the right (but not the obligation) to convert any exercisable but
unexercised portion of this Purchase Option into Units (“Conversion Right”) as
follows: upon exercise of the Conversion Right, the Company shall deliver to the
Holder (without payment by the Holder of any of the Exercise Price in cash) that
number of Units (or that number of shares of Common Stock and Warrants
comprising that number of Units) equal to the quotient obtained by dividing (x)
the “Value” (as defined below) of the portion of the Purchase Option being
converted by (y) the Current Market Value (as defined below). The “Value” of the
portion of the Purchase Option being converted shall equal the remainder derived
from subtracting (a) (i) the Exercise Price multiplied by (ii) the number of
Units underlying the portion of this Purchase Option being converted from (b)
the Current Market Value of a Unit multiplied by the number of Units underlying
the portion of the Purchase Option being converted. As used herein, the term
“Current Market Value” per Unit at any date means (A) in the event that neither
the Units nor Warrants are still trading, the remainder derived from subtracting
(x) the exercise price of the Warrants multiplied by the number of shares of
Common Stock issuable upon exercise of the Warrants underlying one Unit from (y)
(i) the Current Market Price of the Common Stock multiplied by (ii) the number
of shares of Common Stock underlying one Unit, which shall include the shares of
Common Stock underlying the Warrants included in such Unit; (B) in the event
that the Units, Common Stock and Warrants are still trading, (i) if the Units
are listed on a national securities exchange or quoted on the Nasdaq National
Market, Nasdaq SmallCap Market or NASD OTC Bulletin Board (or successor such as
the Bulletin Board Exchange), the last sale price of the Units in the principal
trading market for the Units as reported by the exchange, Nasdaq or the NASD, as
the case may be, on the last trading day preceding the date in question; or (ii)
if the Units are not listed on a national securities exchange or quoted on the
Nasdaq National Market, Nasdaq SmallCap Market or the NASD OTC Bulletin Board
(or successor exchange), but is traded in the residual over-the-counter market,
the closing bid price for Units on the last trading day preceding the date in
question for which such quotations are reported by the Pink Sheets, LLC or
similar publisher of such quotations; and (C) in the event that the Units are
not still trading but the Common Stock and Warrants underlying the Units are
still trading, the Current Market Price of the Common Stock plus the product of
(x) the Current Market Price of the Warrants and (y) the number of shares of
Common Stock underlying the Warrants included in one Unit. The
"Current Market Price" shall mean (i) if the Common Stock (or Warrants, as the
case may be) is listed on a national securities exchange or quoted on the Nasdaq
National Market, Nasdaq SmallCap Market or NASD OTC Bulletin Board (or successor
such as the Bulletin Board Exchange), the last sale price of the Common Stock
(or Warrants) in the principal trading market for the Common Stock as reported
by the exchange, Nasdaq or the NASD, as the case may be, on the last trading day
preceding the date in question; (ii) if the Common Stock (or Warrants, as the
case may be) is not listed on a national securities exchange or quoted on the
Nasdaq National Market, Nasdaq SmallCap Market or the NASD OTC Bulletin Board
(or successor exchange), but is traded in the residual over-the-counter market,
the closing bid price for the Common Stock (or Warrants) on the last trading day
preceding the date in question for which such quotations are reported by the
Pink Sheets, LLC or similar publisher of such quotations; and (iii) if the fair
market value of the Common Stock cannot be determined pursuant to clause (i) or
(ii) above, such price as the Board of Directors of the Company shall determine,
in good faith.

 

2.3.2  Mechanics
of Cashless Exercise. The
Cashless Exercise Right may be exercised by the Holder on any business day on or
after the Commencement Date and not later than the Expiration Date by delivering
the Purchase Option with the duly executed exercise form attached hereto with
the cashless exercise section completed to the Company, exercising the Cashless
Exercise Right and specifying the total number of Units the Holder will purchase
pursuant to such Cashless Exercise Right.

 

2

3.  Transfer.

 

3.1  General
Restrictions. The
registered Holder of this Purchase Option, by its acceptance hereof, agrees that
it will not sell, transfer, assign, pledge or hypothecate this Purchase Option
for a period of one year following the Effective Date to anyone other than (i)
Sunrise or an underwriter or a selected dealer in connection with the Offering,
or (ii) a bona fide officer or partner of Sunrise or of any such underwriter or
selected dealer. On and after the first anniversary of the Effective Date,
transfers to others may be made subject to compliance with or exemptions from
applicable securities laws. In order to make any permitted assignment, the
Holder must deliver to the Company the assignment form attached hereto duly
executed and completed, together with the Purchase Option and payment of all
transfer taxes, if any, payable in connection therewith. The Company shall
within five business days transfer this Purchase Option on the books of the
Company and shall execute and deliver a new Purchase Option or Purchase Options
of like tenor to the appropriate assignee(s) expressly evidencing the right to
purchase the aggregate number of Units purchasable hereunder or such portion of
such number as shall be contemplated by any such assignment.

 

3.2  Restrictions
Imposed by the Act. The
securities evidenced by this Purchase Option shall not be transferred unless and
until (i) the Company has received the opinion of counsel for the Holder that
the securities may be transferred pursuant to an exemption from registration
under the Act and applicable state securities laws, the availability of which is
established to the reasonable satisfaction of the Company (the Company hereby
agreeing that the opinion of Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
(“Mintz Levin”) shall be deemed satisfactory evidence of the availability of an
exemption), or (ii) a registration statement or a post-effective amendment to
the Registration Statement relating to such securities has been filed by the
Company and declared effective by the Securities and Exchange Commission and
compliance with applicable state securities law has been
established.

 

4.  New
Purchase Options to be Issued.

 

4.1  Partial
Exercise or Transfer. Subject
to the restrictions in Section 3 hereof, this Purchase Option may be exercised
or assigned in whole or in part. In the event of the exercise or assignment
hereof in part only, upon surrender of this Purchase Option for cancellation,
together with the duly executed exercise or assignment form and funds sufficient
to pay any Exercise Price and/or transfer tax, the Company shall cause to be
delivered to the Holder without charge a new Purchase Option of like tenor to
this Purchase Option in the name of the Holder evidencing the right of the
Holder to purchase the number of Units purchasable hereunder as to which this
Purchase Option has not been exercised or assigned.

 

4.2  Lost
Certificate. Upon
receipt by the Company of evidence satisfactory to it of the loss, theft,
destruction or mutilation of this Purchase Option and of reasonably satisfactory
indemnification or the posting of a bond, the Company shall execute and deliver
a new Purchase Option of like tenor and date. Any such new Purchase Option
executed and delivered as a result of such loss, theft, mutilation or
destruction shall constitute a substitute contractual obligation on the part of
the Company.

 

5.  Registration
Rights.

 

5.1  Demand
Registration.

 

5.1.1  Grant
of Right. The
Company, upon written demand (“Initial Demand Notice”) of the Holder(s) of at
least 51% of the Purchase Options and/or the underlying Units and/or the
underlying securities (“Majority Holders”), agrees to register on one occasion,
all or any portion of the Purchase Options requested by the Majority Holders in
the Initial Demand Notice and all of the securities underlying such Purchase
Options, including the Units, Common Stock, the Warrants and the Common Stock
underlying the Warrants (collectively, the “Registrable Securities”). On such
occasion, the Company will file a registration statement or a post-effective
amendment to the Registration Statement covering the Registrable Securities
within sixty days after receipt of the Initial Demand Notice and use its best
efforts to have such registration statement or post-effective amendment declared
effective as soon as possible thereafter. The demand for registration may be
made at any time during a period of five years beginning on the Effective Date.
The Company covenants and agrees to give written notice of its receipt of any
Initial Demand Notice by any Holder(s) to all other registered Holders of the
Purchase Options and/or the Registrable Securities within ten days from the date
of the receipt of any such Initial Demand Notice.

 

3

5.1.2  Terms. The
Company shall bear all fees and expenses attendant to registering the
Registrable Securities, including the expenses of any legal counsel selected by
the Holders to represent them in connection with the sale of the Registrable
Securities, but the Holders shall pay any and all underwriting commissions,
discounts and transfer taxes, if any. The Company agrees to use its reasonable
best efforts to qualify or register the Registrable Securities in such States as
are reasonably requested by the Majority Holder(s); provided, however, that in
no event shall the Company be required to register the Registrable Securities in
a State in which such registration would cause (i) the Company to be obligated
to qualify to do business in such State, or would subject the Company to
taxation as a foreign corporation doing business in such jurisdiction or (ii)
the principal stockholders of the Company to be obligated to escrow their shares
of capital stock of the Company. The Company shall cause any registration
statement or post-effective amendment filed pursuant to the demand rights
granted under Section 5.1.1 to remain effective for a period of twelve
consecutive months from the effective date of such registration statement or
post-effective amendment.

 

5.2  “Piggy-Back”
Registration.

 

5.2.1  Grant
of Right. In
addition to the demand right of registration, the Holders of the Purchase
Options shall have the right for a period of seven years commencing on the
Effective Date, to include the Registrable Securities as part of any other
registration of securities filed by the Company (other than in connection with a
transaction contemplated by Rule 145(a) promulgated under the Act or pursuant to
Form S-8); provided, however, that if, in the written opinion of the Company’s
managing underwriter or underwriters, if any, for such offering, the inclusion
of the Registrable Securities, when added to the securities being registered by
the Company or the selling stockholder(s), will exceed the maximum amount of the
Company’s securities (“Maximum Number of Shares”) which can be marketed (i) at a
price reasonably related to their then current market value, and (ii) without
materially and adversely affecting the entire offering, then the Company shall
include in any such registration: (a) If
the registration is undertaken for the Company's account: (A) first, the shares
of Common Stock or other securities that the Company desires to sell that can be
sold without exceeding the Maximum Number of Shares; (B) second, to the extent
that the Maximum Number of Shares has not been reached under the foregoing
clause (A), the shares of Common Stock, if any, including the Registrable
Securities, as to which registration has been requested pursuant to written
contractual piggy-back registration rights of security holders (pro rata in
accordance with the number of shares of Common Stock which each such person has
actually requested to be included in such registration, regardless of the number
of shares of Common Stock with respect to which such persons have the right to
request such inclusion) that can be sold without exceeding the Maximum Number of
Shares; and (b) If the registration is a "demand" registration undertaken at the
demand of persons other than the holders of Registrable Securities pursuant to
written contractual arrangements with such persons, (A)first, the shares of
Common Stock for the account of the demanding persons that can be sold without
exceeding the Maximum Number of Shares; (B) second, to the extent that the
Maximum Number of Shares has not been reached under the foregoing clause (A),
the shares of Common Stock or other securities that the Company desires to sell
that can be sold without exceeding the Maximum Number of Shares; and (C) third,
to the extent that the Maximum Number of Shares has not been reached under the
foregoing clauses (A) and (B), the Registrable Securities as to which
registration has been requested under this Section 5.2 (pro rata in accordance
with the number of shares of Registrable Securities held by each such holder);
and (D) fourth, to the extent that the Maximum Number of Shares has not been
reached under the foregoing clauses (A), (B) and (C), the shares of Common
Stock, if any, as to which registration has been requested pursuant to written
contractual piggy-back registration rights which other shareholders desire to
sell that can be sold without exceeding the Maximum Number of
Shares.

 

5.2.2  Terms. The
Company shall bear all fees and expenses attendant to registering the
Registrable Securities, including the expenses of any legal counsel selected by
the Holders to represent them in connection with the sale of the Registrable
Securities but the Holders shall pay any and all underwriting commissions,
discounts and transfer taxes, if any, related to the Registrable Securities. In
the event of such a proposed registration, the Company shall furnish the then
Holders of outstanding Registrable Securities with not less than fifteen days
written notice prior to the proposed date of filing of such registration
statement. Such notice to the Holders shall continue to be given for each
applicable registration statement filed (during the period in which the Purchase
Option is exercisable) by the Company until such time as all of the Registrable
Securities have been registered and sold. The holders of the Registrable
Securities shall exercise the “piggy-back” rights provided for herein by giving
written notice, within ten days of the receipt of the Company’s notice of its
intention to file a registration statement. The Company shall cause any
registration statement filed pursuant to the above “piggyback” rights to remain
effective for at least nine months from the date that the Holders of the
Registrable Securities are first given the opportunity to sell all of such
securities.

 

4

5.3  Damages. Should
the registration or the effectiveness thereof required by Sections 5.1 and 5.2
hereof be delayed by the Company or the Company otherwise fails to comply with
such provisions, the Company shall, in addition to any other equitable or other
relief available to the Holder(s), be liable for any and all incidental, special
and consequential damages sustained by the Holder(s), including, but not limited
to, the loss of any profits that might have been received by the holder upon the
sale of shares of Common Stock or Warrants (and shares of Common Stock
underlying the Warrants) underlying this Purchase Option.

 

5.4  General
Terms.

 

5.4.1  Indemnification. The
Company shall indemnify the Holder(s) of the Registrable Securities to be sold
pursuant to any registration statement hereunder and each person, if any, who
controls such Holders within the meaning of Section 15 of the Act or Section
20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”),
against all loss, claim, damage, expense or liability (including all reasonable
attorneys’ fees and other expenses reasonably incurred in investigating,
preparing or defending against litigation, commenced or threatened, or any claim
whatsoever whether arising out of any action between the underwriter and the
Company or between the underwriter and any third party or otherwise) to which
any of them may become subject under the Act, the Exchange Act or otherwise,
arising from such registration statement but only to the same extent and with
the same effect as the provisions pursuant to which the Company has agreed to
indemnify the underwriters contained in Section 5 of the Underwriting Agreement
between the Company, Sunrise and the other underwriters named therein dated the
Effective Date. The Holder(s) of the Registrable Securities to be sold pursuant
to such registration statement, and their successors and assigns, shall
severally, and not jointly, indemnify the Company, its officers and directors
and each person, if any, who controls the Company within the meaning of Section
15 of the Act or Section 20(a) of the Exchange Act, against all loss, claim,
damage, expense or liability (including all reasonable attorneys’ fees and other
expenses reasonably incurred in investigating, preparing or defending against
any claim whatsoever) to which they may become subject under the Act, the
Exchange Act or otherwise, arising from information furnished by or on behalf of
such Holders, or their successors or assigns, in writing, for specific inclusion
in such registration statement to the same extent and with the same effect as
the provisions contained in Section 5 of the Underwriting Agreement pursuant to
which the underwriters have agreed to indemnify the Company.

 

5.4.2  Exercise
of Purchase Options. Nothing
contained in this Purchase Option shall be construed as requiring the Holder(s)
to exercise their Purchase Options or Warrants underlying such Purchase Options
prior to or after the initial filing of any registration statement or the
effectiveness thereof.

 

5.4.3  Documents
Delivered to Holders. The
Company shall furnish Sunrise, as representative of the Holders participating in
any of the foregoing offerings, a signed counterpart, addressed to the
participating Holders, of (i) an opinion of counsel to the Company, dated the
effective date of such registration statement (and, if such registration
includes an underwritten public offering, an opinion dated the date of the
closing under any underwriting agreement related thereto), and (ii) a “cold
comfort” letter dated the effective date of such registration statement (and, if
such registration includes an underwritten public offering, a letter dated the
date of the closing under the underwriting agreement) signed by the independent
public accountants who have issued a report on the Company’s financial
statements included in such registration statement, in each case covering
substantially the same matters with respect to such registration statement (and
the prospectus included therein) and, in the case of such accountants’ letter,
with respect to events subsequent to the date of such financial statements, as
are customarily covered in opinions of issuer’s counsel and in accountants’
letters delivered to underwriters in underwritten public offerings of
securities. The Company shall also deliver promptly to Sunrise, as
representative of the Holders participating in the offering, the correspondence
and memoranda described below and copies of all correspondence between the
Commission and the Company, its counsel or auditors and all memoranda relating
to discussions with the Commission or its staff with respect to the registration
statement and permit Sunrise, as representative of the Holders, to do such
investigation, upon reasonable advance notice, with respect to information
contained in or omitted from the registration statement as it deems reasonably
necessary to comply with applicable securities laws or rules of the National
Association of Securities Dealers, Inc (“NASD”). Such investigation shall
include access to books, records and properties and opportunities to discuss the
business of the Company with its officers and independent auditors, all to such
reasonable extent and at such reasonable times and as often as Sunrise, as
representative of the Holders, shall reasonably request. The Company shall not
be required to disclose any confidential information or other records to
Sunrise, as representative of the Holders, or to any other person, until and
unless such persons shall have entered into reasonable confidentiality
agreements (in form and substance reasonably satisfactory to the Company), with
the Company with respect thereto.

 

5

5.4.4  Underwriting
Agreement. The
Company shall enter into an underwriting agreement with the managing
underwriter(s), if any, selected by any Holders whose Registrable Securities are
being registered pursuant to this Section 5, which managing underwriter shall be
reasonably acceptable to the Company. Such agreement shall be reasonably
satisfactory in form and substance to the Company, each Holder and such managing
underwriters, and shall contain such representations, warranties and covenants
by the Company and such other terms as are customarily contained in agreements
of that type used by the managing underwriter. The Holders shall be parties to
any underwriting agreement relating to an underwritten sale of their Registrable
Securities and may, at their option, require that any or all the
representations, warranties and covenants of the Company to or for the benefit
of such underwriters shall also be made to and for the benefit of such Holders.
Such Holders shall not be required to make any representations or warranties to
or agreements with the Company or the underwriters except as they may relate to
such Holders and their intended methods of distribution. Such Holders, however,
shall agree to such covenants and indemnification and contribution obligations
for selling stockholders as are customarily contained in agreements of that type
used by the managing underwriter. Further, such Holders shall execute
appropriate custody agreements and otherwise cooperate fully in the preparation
of the registration statement and other documents relating to any offering in
which they include securities pursuant to this Section 5. Each Holder shall also
furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be reasonably required to effect the registration of the Registrable
Securities.

 

5.4.5  Rule
144 Sale.
Notwithstanding anything contained in this Section 5 to the contrary, the
Company shall have no obligation pursuant to Sections 5.1 or 5.2 for the
registration of Registrable Securities held by any Holder (i) where such Holder
would then be entitled to sell under Rule 144 within any three-month period (or
such other period prescribed under Rule 144 as may be provided by amendment
thereof) all of the Registrable Securities then held by such Holder, and (ii)
where the number of Registrable Securities held by such Holder is within the
volume limitations under paragraph (e) of Rule 144 (calculated as if such Holder
were an affiliate within the meaning of Rule 144).

 

5.4.6  Supplemental
Prospectus. Each
Holder agrees, that upon receipt of any notice from the Company of the happening
of any event as a result of which the prospectus included in the Registration
Statement, as then in effect, includes an untrue statement of a material fact or
omits to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in light of the circumstances then
existing, such Holder will immediately discontinue disposition of Registrable
Securities pursuant to the Registration Statement covering such Registrable
Securities until such Holder’s receipt of the copies of a supplemental or
amended prospectus, and, if so desired by the Company, such Holder shall deliver
to the Company (at the expense of the Company) or destroy (and deliver to the
Company a certificate of such destruction) all copies, other than permanent file
copies then in such Holder’s possession, of the prospectus covering such
Registrable Securities current at the time of receipt of such
notice.

 

6.  Adjustments.

 

6.1  Adjustments
to Exercise Price and Number of Securities. The
Exercise Price and the number of Units underlying the Purchase Option shall be
subject to adjustment from time to time as hereinafter set forth:

 

6.1.1  Stock
Dividends - Split-Ups. If
after the date hereof, and subject to the provisions of Section 6.4 below, the
number of outstanding shares of Common Stock is increased by a stock dividend
payable in shares of Common Stock or by a split-up of shares of Common Stock or
other similar event, then, on the effective date thereof, the number of shares
of Common Stock underlying each of the Units purchasable hereunder shall be
increased in proportion to such increase in outstanding shares. In such case,
the number of shares of Common Stock, and the exercise price applicable thereto,
underlying the Warrants underlying each of the Units purchasable hereunder shall
be adjusted in accordance with the terms of the Warrants. For example, if the
Company declares a two-for-one stock dividend and at the time of such dividend
this Purchase Option is for the purchase of one Unit at $6.60 per whole Unit
(each Warrant underlying the Units is exercisable for $5.00 per share), upon
effectiveness of the dividend, this Purchase Option will be adjusted to allow
for the purchase of one Unit at $6.60 per Unit, each Unit entitling the holder
to receive two shares of Common Stock and four Warrants (each Warrant
exercisable for $2.50 per share).

 

6

6.1.2  Aggregation
of Shares. If
after the date hereof, and subject to the provisions of Section 6.4, the number
of outstanding shares of Common Stock is decreased by a consolidation,
combination or reclassification of shares of Common Stock or other similar
event, then, on the effective date thereof, the number of shares of Common Stock
underlying each of the Units purchasable hereunder shall be decreased in
proportion to such decrease in outstanding shares. In such case, the number of
shares of Common Stock, and the exercise price applicable thereto, underlying
the Warrants underlying each of the Units purchasable hereunder shall be
adjusted in accordance with the terms of the Warrants.

 

6.1.3  Replacement
of Securities upon Reorganization, etc. In case
of any reclassification or reorganization of the outstanding shares of Common
Stock other than a change covered by Section 6.1.1 or 6.1.2 hereof or that
solely affects the par value of such shares of Common Stock, or in the case of
any merger or consolidation of the Company with or into another corporation
(other than a consolidation or merger in which the Company is the continuing
corporation and that does not result in any reclassification or reorganization
of the outstanding shares of Common Stock), or in the case of any sale or
conveyance to another corporation or entity of the property of the Company as an
entirety or substantially as an entirety in connection with which the Company is
dissolved, the Holder of this Purchase Option shall have the right thereafter
(until the expiration of the right of exercise of this Purchase Option) to
receive upon the exercise hereof, for the same aggregate Exercise Price payable
hereunder immediately prior to such event, the kind and amount of shares of
stock or other securities or property (including cash) receivable upon such
reclassification, reorganization, merger or consolidation, or upon a dissolution
following any such sale or transfer, by a Holder of the number of shares of
Common Stock of the Company obtainable upon exercise of this Purchase Option and
the underlying Warrants immediately prior to such event; and if any
reclassification also results in a change in shares of Common Stock covered by
Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant to Sections
6.1.1, 6.1.2 and this Section 6.1.3 The provisions of this Section 6.1.3 shall
similarly apply to successive reclassifications, reorganizations, mergers or
consolidations, sales or other transfers.

 

6.1.4  Changes
in Form of Purchase Option. This
form of Purchase Option need not be changed because of any change pursuant to
this Section, and Purchase Options issued after such change may state the same
Exercise Price and the same number of Units as are stated in the Purchase
Options initially issued pursuant to this Agreement. The acceptance by any
Holder of the issuance of new Purchase Options reflecting a required or
permissive change shall not be deemed to waive any rights to an adjustment
occurring after the Commencement Date or the computation thereof.

 

6.2  [Intentionally
Omitted].

 

6.3  Substitute
Purchase Option. In case
of any consolidation of the Company with, or merger of the Company with, or
merger of the Company into, another corporation (other than a consolidation or
merger which does not result in any reclassification or change of the
outstanding Common Stock), the corporation formed by such consolidation or
merger shall execute and deliver to the Holder a supplemental Purchase Option
providing that the holder of each Purchase Option then outstanding or to be
outstanding shall have the right thereafter (until the stated expiration of such
Purchase Option) to receive, upon exercise of such Purchase Option, the kind and
amount of shares of stock and other securities and property receivable upon such
consolidation or merger, by a holder of the number of shares of Common Stock of
the Company for which such Purchase Option might have been exercised immediately
prior to such consolidation, merger, sale or transfer. Such supplemental
Purchase Option shall provide for adjustments which shall be identical to the
adjustments provided in Section 6. The above provision of this Section shall
similarly apply to successive consolidations or mergers.

 

6.4  Elimination
of Fractional Interests. The
Company shall not be required to issue certificates representing fractions of
shares of Common Stock or Warrants upon the exercise of the Purchase Option, nor
shall it be required to issue scrip or pay cash in lieu of any fractional
interests, it being the intent of the parties that all fractional interests
shall be eliminated by rounding any fraction up to the nearest whole number of
Warrants, shares of Common Stock or other securities, properties or
rights.

 

7

7.  Reservation
and Listing. The
Company shall at all times reserve and keep available out of its authorized
shares of Common Stock, solely for the purpose of issuance upon exercise of the
Purchase Options or the Warrants underlying the Purchase Option, such number of
shares of Common Stock or other securities, properties or rights as shall be
issuable upon the exercise thereof. The Company covenants and agrees that, upon
exercise of the Purchase Options and payment of the Exercise Price therefor, all
shares of Common Stock and other securities issuable upon such exercise shall be
duly and validly issued, fully paid and non-assessable and not subject to
preemptive rights of any stockholder. The Company further covenants and agrees
that upon exercise of the Warrants underlying the Purchase Options and payment
of the respective Warrant exercise price therefor, all shares of Common Stock
and other securities issuable upon such exercise shall be duly and validly
issued, fully paid and non-assessable and not subject to preemptive rights of
any stockholder. As long as the Purchase Options shall be outstanding, the
Company shall use its best efforts to cause all (i) Units and shares of Common
Stock issuable upon exercise of the Purchase Options, (iii) Warrants issuable
upon exercise of the Purchase Options and (iv) shares of Common Stock issuable
upon exercise of the Warrants included in the Units issuable upon exercise of
the Purchase Option to be listed (subject to official notice of issuance) on all
securities exchanges (or, if applicable on the Nasdaq National Market, SmallCap
Market, OTC Bulletin Board or any successor trading market) on which the Units,
the Common Stock or the Public Warrants issued to the public in connection
herewith may then be listed and/or quoted.

 

8.  Certain
Notice Requirements.

 

8.1  Holder’s
Right to Receive Notice. Nothing
herein shall be construed as conferring upon the Holders the right to vote or
consent as a stockholder for the election of directors or any other matter, or
as having any rights whatsoever as a stockholder of the Company. If, however, at
any time prior to the expiration of the Purchase Options and their exercise, any
of the events described in Section 8.2 shall occur, then, in one or more of said
events, the Company shall give written notice of such event at least fifteen
days prior to the date fixed as a record date or the date of closing the
transfer books for the determination of the stockholders entitled to such
dividend, distribution, conversion or exchange of securities or subscription
rights, or entitled to vote on such proposed dissolution, liquidation, winding
up or sale. Such notice shall specify such record date or the date of the
closing of the transfer books, as the case may be. Notwithstanding the
foregoing, the Company shall deliver to each Holder a copy of each notice given
to the other stockholders of the Company at the same time and in the same manner
that such notice is given to the stockholders.

 

8.2  Events
Requiring Notice. The
Company shall be required to give the notice described in this Section 8 upon
one or more of the following events: (i) if the Company shall take a record of
the holders of its shares of Common Stock for the purpose of entitling them to
receive a dividend or distribution payable otherwise than in cash, or a cash
dividend or distribution payable otherwise than out of retained earnings, as
indicated by the accounting treatment of such dividend or distribution on the
books of the Company, or (ii) the Company shall offer to all the holders of its
Common Stock any additional shares of capital stock of the Company or securities
convertible into or exchangeable for shares of capital stock of the Company, or
any option, right or warrant to subscribe therefor, or (iii) a dissolution,
liquidation or winding up of the Company (other than in connection with a
consolidation or merger) or a sale of all or substantially all of its property,
assets and business shall be proposed.

 

8.3  Notice
of Change in Exercise Price. The
Company shall, promptly after an event requiring a change in the Exercise Price
pursuant to Section 6 hereof, send notice to the Holders of such event and
change (“Price Notice”). The Price Notice shall describe the event causing the
change and the method of calculating same and shall be certified as being true
and accurate by the Company’s President and Chief Financial
Officer.

 

8.4  Transmittal
of Notices. All
notices, requests, consents and other communications under this Purchase Option
shall be in writing and shall be deemed to have been duly made when hand
delivered, or mailed by express mail or private courier service: (i) If to the
registered Holder of the Purchase Option, to the address of such Holder as shown
on the books of the Company, or (ii) if to the Company, to the following address
or to such other address as the Company may designate by notice to the
Holders:

 

8

 

Fortress
America Acquisition Corporation

3
Bethesda Metro Center, Suite 700

Bethesda,
MD 20814 

Attn: C.
Thomas McMillen, Chairman

 

9.  Miscellaneous.

 

9.1  Amendments. The
Company and Sunrise may from time to time supplement or amend this Purchase
Option without the approval of any of the Holders in order to cure any
ambiguity, to correct or supplement any provision contained herein that may be
defective or inconsistent with any other provisions herein, or to make any other
provisions in regard to matters or questions arising hereunder that the Company
and Sunrise may deem necessary or desirable and that the Company and Sunrise
deem shall not adversely affect the interest of the Holders. All other
modifications or amendments shall require the written consent of and be signed
by the party against whom enforcement of the modification or amendment is
sought.

 

9.2  Headings. The
headings contained herein are for the sole purpose of convenience of reference,
and shall not in any way limit or affect the meaning or interpretation of any of
the terms or provisions of this Purchase Option.

 

10.  Entire
Agreement. This
Purchase Option (together with the other agreements and documents being
delivered pursuant to or in connection with this Purchase Option) constitutes
the entire agreement of the parties hereto with respect to the subject matter
hereof, and supersedes all prior agreements and understandings of the parties,
oral and written, with respect to the subject matter hereof.

 

10.1  Binding
Effect. This
Purchase Option shall inure solely to the benefit of and shall be binding upon,
the Holder and the Company and their permitted assignees, respective successors,
legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or
by virtue of this Purchase Option or any provisions herein
contained.

 

10.2  Governing
Law; Submission to Jurisdiction. This
Purchase Option shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of
laws. The Company hereby agrees that any action, proceeding or claim against it
arising out of, or relating in any way to this Purchase Option shall be brought
and enforced in the courts of the State of New York or of the United States of
America for the Southern District of New York, and irrevocably submits to such
jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives
any objection to such exclusive jurisdiction and that such courts represent an
inconvenient forum. Any process or summons to be served upon the Company may be
served by transmitting a copy thereof by registered or certified mail, return
receipt requested, postage prepaid, addressed to it at the address set forth in
Section 8 hereof. Such mailing shall be deemed personal service and shall be
legal and binding upon the Company in any action, proceeding or claim. The
Company and the Holder agree that the prevailing party(ies) in any such action
shall be entitled to recover from the other party(ies) all of its reasonable
attorneys’ fees and expenses relating to such action or proceeding and/or
incurred in connection with the preparation therefor.

 

10.3  Waiver,
Etc. The
failure of the Company or the Holder to at any time enforce any of the
provisions of this Purchase Option shall not be deemed or construed to be a
waiver of any such provision, nor to in any way affect the validity of this
Purchase Option or any provision hereof or the right of the Company or any
Holder to thereafter enforce each and every provision of this Purchase Option.
No waiver of any breach, non-compliance or non-fulfillment of any of the
provisions of this Purchase Option shall be effective unless set forth in a
written instrument executed by the party or parties against whom or which
enforcement of such waiver is sought; and no waiver of any such breach,
non-compliance
or non-fulfillment shall be construed or deemed to be a waiver of any other or
subsequent breach, non-compliance or non-fulfillment.

 

10.4  Execution
in Counterparts. This
Purchase Option may be executed in one or more counterparts, and by the
different parties hereto in separate counterparts, each of which shall be deemed
to be an original, but all of which taken together shall constitute one and the
same agreement, and shall become effective when one or more counterparts has
been signed by each of the parties hereto and delivered to each of the other
parties hereto.

 

9

10.5  Exchange
Agreement. As a
condition of the Holder’s receipt and acceptance of this Purchase Option, Holder
agrees that, at any time prior to the complete exercise of this Purchase Option
by Holder, if the Company and Sunrise enter into an agreement (“Exchange
Agreement”) pursuant to which they agree that all outstanding Purchase Options
will be exchanged for securities or cash or a combination of both, then Holder
shall agree to such exchange and become a party to the Exchange
Agreement.

 

10.6  Underlying
Warrants. At any
time after exercise by the Holder of this Purchase Option, the Holder may
exchange his Warrants (with a $6.25 exercise price) for Public Warrants (with a
$5.00 exercise price) upon payment to the Company of the difference between the
exercise price of his Warrant and the exercise price of the Public
Warrants.

 

10

IN
WITNESS WHEREOF, the Company has caused this Purchase Option to be signed by its
duly authorized officer as of the ____ day of __________, 2005.

 

 

FORTRESS
AMERICA ACQUISITION CORPORATION

 

 

By:    

     Name: C. Thomas
McMillen

       Title: Chairman
of the Board

 

Form to
be used to exercise Purchase Option:

 

Fortress
America Acquisition Corporation

3
Bethesda Metro Center, Suite 700

Bethesda,
MD 20814 

 

Date:_________________,
200__

 

The
undersigned hereby elects irrevocably to exercise all or a portion of the within
Purchase Option and to purchase ____ Units of Fortress America Acquisition
Corporation and hereby makes payment of $____________ (at the rate of $_________
per Unit) in payment of the Exercise Price pursuant thereto. Please issue the
Common Stock and Warrants as to which this Purchase Option is exercised in
accordance with the instructions given below.

 

or

 

The
undersigned hereby elects irrevocably to convert its right to purchase _________
Units purchasable under the within Purchase Option by surrender of the
unexercised portion of the attached Purchase Option (with a “Value” based of
$_______ based on a “Market Price” of $_______). Please issue the securities
comprising the Units as to which this Purchase Option is exercised in accordance
with the instructions given below.

 

 

 

                                                                    

Signature

 

 

                                      

Signature
Guaranteed

 

INSTRUCTIONS
FOR REGISTRATION OF SECURITIES

 

Name        

    (Print in
Block Letters)

 

 

Address                             

 

NOTICE:
THE SIGNATURE TO THIS FORM MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE
FACE OF THE WITHIN PURCHASE OPTION IN EVERY PARTICULAR WITHOUT ALTERATION OR
ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A BANK, OTHER
THAN A SAVINGS BANK, OR BY A TRUST COMPANY OR BY A FIRM HAVING MEMBERSHIP ON A
REGISTERED NATIONAL SECURITIES EXCHANGE.

 

Form to
be used to assign Purchase Option:

 

ASSIGNMENT

 

(To be
executed by the registered Holder to effect a transfer of the within Purchase
Option):

 

FOR VALUE
RECEIVED,___________________________________________ does hereby sell, assign
and transfer unto______________________________________ the right to purchase
__________ Units of Fortress America Acquisition Corporation (“Company”)
evidenced by the within Purchase Option and does hereby authorize the Company to
transfer such right on the books of the Company.

 

Dated:___________________,
200_

 

______________________________

Signature

 

 

______________________________

Signature
Guaranteed

 

NOTICE:
THE SIGNATURE TO THIS FORM MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE
FACE OF THE WITHIN PURCHASE OPTION IN EVERY PARTICULAR WITHOUT ALTERATION OR
ENLARGEMENT OR ANY CHANGE WHATSOEVER, AND MUST BE GUARANTEED BY A BANK, OTHER
THAN A SAVINGS BANK, OR BY A TRUST COMPANY OR BY A FIRM HAVING MEMBERSHIP ON A
REGISTERED NATIONAL SECURITIES EXCHANGE.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00082-of-00352.parquet"}]]